Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

(Reuters) – Merck & Co’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company’s lead in the most lucrative oncology market.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply